Document Detail

A novel cell therapy for stress urinary incontinence, short-term outcome.
MedLine Citation:
PMID:  22972395     Owner:  NLM     Status:  Publisher    
AIMS: The aim of this study was the safety assessment of urethra injections of autologous total nucleated cells (TNCs) along with platelets, which focused on the outcome over a 6 month period. METHODS: An open, prospective study was conducted on 9 patients with severe stress urinary incontinence (SUI). At the baseline, 1, 3, and 6 months after external urethral sphincteric and submucosal injections of autologous TNCs along with platelets, the patients were assessed according to cough tests, Q-Tip tests, urodynamics, 1 hr pad tests, upper tract ultrasonography (UTU), post voiding residue (PVR), International Consultation on Incontinence Questionnaire-Urinary incontinence (ICIQ-UI), and International Consultation on Incontinence Modular Questionnaire-Quality of Life (ICIQ-QOL). On the 3rd month post-injection, the maximum urethral closure pressure (MUCP) and abdominal leak point pressure (ALPP) were measured in one patient with intrinsic sphincteric deficiency (ISD; the baseline: ALPP < 60 and MUCP < 30 cmH(2) O). RESULTS: No complications were observed after injection. At 6-months' follow up (F/U), all the patients considered themselves clinically cured with eight women completely continent and one marked improvement. Mean age was 48.9 ± 13.8 years. Before the injection, urodynamics, UTU, and PVR were normal and cough tests, 1 hr pad tests were positive in patients. At 1, 3, and 6 months post-injection, there was a significant improvement in ICIQ-UI, ICIQ-QOL (P < 0.05). UTU and PVR were normal, cough tests, and 1 hr pad tests were negative, except for ISD patient with severe coughs (at month 3: ALPP = 92 and MUCP > 30 cmH(2) O). CONCLUSION: Cell therapy consisting of intrasphincteric and submucosal injections of autologous TNCs along with platelets in SUI patients is a feasible and safe procedure. The results point out those subjects cured or with marked improvement after 6 months F/U. Neurourol. Urodynam. © 2012 Wiley Periodicals, Inc.
Maliheh Keshvari Shirvan; Daryoush Hamidi Alamdari; Mohammadreza Darabi Mahboub; Alireza Ghanadi; Hamid Reza Rahimi; Alexander M Seifalian
Related Documents :
24659505 - Hip chondropathy at arthroscopy: prevalence and relationship to labral pathology, femor...
23295465 - Igf-i bioactivity might reflect different aspects of quality of life than total igf-i i...
24881635 - Cost-effectiveness of lumbar discectomy and single-level fusion for spondylolisthesis: ...
10414545 - Management of chylothorax after thoracoscopic splanchnicectomy.
11243745 - Can a nine-month regimen be used to treat isoniazid resistant tuberculosis diagnosed af...
23426385 - Protective effects of tranexamic acid on clopidogrel before coronary artery bypass graf...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-9-12
Journal Detail:
Title:  Neurourology and urodynamics     Volume:  -     ISSN:  1520-6777     ISO Abbreviation:  Neurourol. Urodyn.     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-9-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8303326     Medline TA:  Neurourol Urodyn     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Wiley Periodicals, Inc.
Department of Urology, Imam Reza Academic Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hong's grading for evaluating anterior chamber angle width.
Next Document:  Luminescent Neutral Platinum Complexes Bearing an Asymmetric N(^) N(^) N Ligand for High-Performance...